Applied Therapeutics Announces Strategic Review to Maximize Shareholder Value

Applied Therapeutics, a clinical-stage biopharmaceutical company, announced that its Board of Directors has initiated a process to explore strategic alternatives to maximize shareholder value. The company will evaluate mergers, acquisitions, partnerships, joint ventures, and other strategic transactions. As part of the process, Applied Therapeutics is reducing its workforce by approximately 46% and implementing other cost-containment measures. The company's commitment to bringing govorestat to patients with rare diseases remains unchanged.